Search hospitals

>

Kentucky

>

Lexington

Baptist Health Lexington

Claim this profile

Lexington, Kentucky 40503

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Heart Failure

Conducts research for Ovarian Cancer

Conducts research for Non-Small Cell Lung Cancer

323 reported clinical trials

16 medical researchers

Photo of Baptist Health Lexington in LexingtonPhoto of Baptist Health Lexington in LexingtonPhoto of Baptist Health Lexington in Lexington

Summary

Baptist Health Lexington is a medical facility located in Lexington, Kentucky. This center is recognized for care of Lung Cancer, Breast Cancer, Heart Failure, Ovarian Cancer, Non-Small Cell Lung Cancer and other specialties. Baptist Health Lexington is involved with conducting 323 clinical trials across 337 conditions. There are 16 research doctors associated with this hospital, such as Firas Badin, MD, Gery Tomassoni, Michael Jones, and Hope Cottrill.

Area of expertise

1

Lung Cancer

Global Leader

Baptist Health Lexington has run 60 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Baptist Health Lexington has run 49 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Baptist Health Lexington

Ovarian Cancer

Lung Cancer

Breast Cancer

Atrial Fibrillation

Heart Failure

Fallopian Tube Cancer

Non-Small Cell Lung Cancer

Cancer

Breast cancer

Uterine Cancer

Image of trial facility.

LY4170156

for Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Baptist Health Lexington?

Where is Baptist Health Lexington located?

Who should I call to ask about financial aid or insurance network?

What insurance does Baptist Health Lexington accept?

What awards or recognition has Baptist Health Lexington received?